John D. Baxter

John D. Baxter

Infectious Disease | Child and Adolescent Psychiatry
3 Cooper Plaza, Sheridan Pavilion
Suite 403
Camden, NJ 08103

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024.

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024.

Journal: Open forum infectious diseases
Published: May 17, 2025

Is There Value in Performing Yearly Screening for Latent Tuberculosis Infection by Interferon-Gamma Release Assay Among Patients Living With HIV in Non-Endemic Settings?

Is There Value in Performing Yearly Screening for Latent Tuberculosis Infection by Interferon-Gamma Release Assay Among Patients Living With HIV in Non-Endemic Settings?

Journal: Open forum infectious diseases
Published: May 15, 2025

Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study.

Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study.

Journal: HIV medicine
Published: July 03, 2023

Injection Drug Use and Healthcare Utilization in Patients Newly Diagnosed With HIV.

Injection Drug Use and Healthcare Utilization in Patients Newly Diagnosed With HIV.

Journal: Journal of addiction medicine
Published: September 12, 2021

Genotypic Characterization of Clinical Klebsiella spp. Isolates Collected From Patients With Suspected Community-Onset Sepsis, Sweden.

Genotypic Characterization of Clinical Klebsiella spp. Isolates Collected From Patients With Suspected Community-Onset Sepsis, Sweden.

Journal: Frontiers in microbiology
Published: December 16, 2020

Changes in neurocognitive assessment scores after initiating dolutegravir- versus elvitegravir-based antiretroviral therapy.

Changes in neurocognitive assessment scores after initiating dolutegravir- versus elvitegravir-based antiretroviral therapy.

Journal: AIDS care
Published: October 26, 2020

Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.

Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.

Journal: HIV medicine
Published: August 05, 2020

Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.

Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.

Journal: HIV medicine
Published: June 19, 2020

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

Journal: Medicine
Published: February 13, 2016

High-quality collection and disposal of WEEE: Environmental impacts and resultant issues.

High-quality collection and disposal of WEEE: Environmental impacts and resultant issues.

Journal: Waste management (New York, N.Y.)
Published: October 01, 2015

Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.

Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.

Journal: Antiviral therapy
Published: August 17, 2015

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Journal: HIV medicine
Published: November 21, 2014
Showing 1-12 of 20

Last Updated: 09/26/2026